ArticleInflammopharmacology2026
Inhibitor of hyaluronic acid synthesis 4-methylumbelliferone (4-MU) as a potential anti-inflammatory substance in acute neuroinflammation model in vivo.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 4-methylumbelliferone attenuates amyloid pathology and learning deficits in the APP/PS1 mouse model.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cytokine and oxylipin profiles in rat brain homogenates were characterized as an inflammatory response 6 h after a single intracerebroventricular injection of LPS (19.3 µg LPS/ventricle), serving as a model of the inflammatory process in trauma, stroke, and similar stroke-like conditions that cause acute reactions. The potential use of 4-methylumbelliferone (4-MU), an inhibitor of hyaluronic acid (HA) synthesis, clinically approved for the treatment of bile spasm, as an anti-inflammatory drug in the early stages of the brain's response to a damaging stimulus was evaluated. i.c.v. injection of LPS induced proinflammatory genes expression (TNFα, IL-6 and IL-1β) and oxylipins synthesis. Simultaneous addition of 4-MU with LPS reduced LPS-induced TNFα, IL-1β, IL-6 release and reduced the increase in COX-derived metabolites-PGF
Indexed as
Identifiers
41331378What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.